Neil Versel

The stock opened at $18 per share, valuing the Switzerland- and Boston-based bioinformatics company at $1.14 billion.

The German bioinformatics startup recently partnered with Genomics England and Genomenon as it seeks to accelerate and bring transparency to genetic testing processes.

EMR integrator Jase Health is embedding molecular diagnostics data from AccessDx Laboratories into clinical workflows for hospitals and LTC facilities.

In a paper published in Nature, Brigham and Women's researchers describe a novel computational pathology method to improve diagnosis and treatment of metastatic cancers.

Fresh off a $13 million round of venture capital, the company said it sees global potential in analyzing hereditary conditions.

French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.

The company has issued a call for the 2,500 independent MDx labs across the US to join together in an effort to double SARS-CoV-2 testing capacity.

Founded by former Inteliquet CEO Carla Balch, the firm is building on visualization technology to help physicians incorporate MDx testing into their practice. 

Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.

NantHealth CEO Patrick Soon-Shiong said that the company is seeking a fast-track FDA clearance predicated on Memorial Sloan Kettering's 468-gene panel.